Intensive insulin therapy to control blood glucose has been found to reduce mortality among critically ill patients in a surgical intensive care unit, though a simple prescriptive insulin infusion protocol to achieve this has not been published previously. This study documents the development and routine use of a simple prescriptive intravenous insulin infusion protocol for critically ill patients and compares the results with previous practice. During development the protocol was optimized and practical issues of implementation addressed. The optimized protocol was then used for all ICU admissions, and a prospectively defined retrospective chart audit performed for the first month of use. Results were compared with a similar time period the previous year. In September 2002, 27 admissions were started on the protocol. Blood glucose for the time on the protocol had a median value of 6.2 (IQR 5.9-7.1) mmol/l compared with 9. 2 (IQR 8.1-10 .2) mmol/l for those on insulin in 2001. Blood glucose for the whole ICU stay for those on the protocol in 2002 had a median value of 6.6 (IQR 6.0-7.4) mmol/l compared with 8.6 (IQR 8.0-9.4) mmol/l in 2001. Blood glucose for all ICU patients in 2002
Intensive insulin therapy to control blood glucose between 4.4 and 6.1 mmol/l has been found to reduce mortality for surgical intensive care unit (ICU) patients 1 . The protocol for intensive insulin therapy used in the study 2, 3 provides guidance rather than strict instructions on insulin doses and so requires some clinical judgement to be made. In the study the dose of insulin was adjusted by intensive care nurses assisted by a study physician. Other published protocols for intravenous insulin infusions have either had a higher target range of blood glucose 4, 5 or have not been evaluated in critical illness [6] [7] [8] [9] [10] [11] [12] . To alleviate the need for clinical judgement (and the inherent errors evoked) in deciding insulin doses when using intensive insulin therapy, a simple prescriptive protocol was developed to enable ICU bedside nursing staff alone to control blood glucose between 4 and 7 mmol/l. This report documents the audits performed during the development and introduction of this protocol. It includes a retrospective analysis of glucose management during the first month of routine use which is compared with glucose management during a similar time period twelve months previously.
MATERIALS AND METHODS

Study Population
The protocol was developed between March 2002 and August 2002 at the Royal United Hospital, Bath, which is a District General Hospital with an elevenbed ICU admitting approximately 750 medical and surgical intensive and high dependency care patients annually. During development, the protocol was used on a maximum of two patients concurrently to allow close monitoring of safety and effectiveness, and to allow medical and nursing staff to increase their understanding about correct use of the protocol. After 1 September 2002 the protocol was used routinely, by which time all staff were familiar with the protocol. All ICU admissions except those aged less than 16 years, those with diabetic ketoacidosis or those having an oral diet were considered eligible for the protocol. The protocol specified that insulin should be started if blood glucose was greater than 7 mmol/l.
Insulin Infusion
An intravenous infusion of human soluble insulin (Actrapid, Novo Nordisk) diluted to 1 IU/ml with 0.9% saline was used. The initial insulin infusion rate chosen was dependent on the initial blood glucose. Subsequent changes to the infusion rate were made after comparing the latest blood glucose both to the target range and also to the previous blood glucose value.
Blood Glucose Measurement
Blood glucose was measured at the bedside immediately after the sampling of undiluted blood. Arterial samples were used preferentially. For patients without an arterial cannula, a venous or finger-prick sample was used. Increased frequency of use of the ICU blood gas analyser during the development phase was associated with more analyser failures, so during routine bedside testing was performed using an individual glucose meter (Accu-Chek Advantage II, Roche, Indianapolis, U.S.A.) for each patient.
Audits Performed 1. Development Phase
Quantitative and qualitative audits of the protocol were performed on a total of 79 patients placed on the insulin protocol during development.
The hourly changes in blood glucose and insulin doses of all those started on the protocol were audited daily. Qualitative audit was also undertaken during this time. All nursing and medical staff were encouraged to provide verbal and written feedback relating to the practical use of the protocol. The information gained during the development phase enabled us to make modifications until the final protocol and guidance notes were optimized.
Audit of the First Month of Routine Use
The audit performed during routine use of the optimized final protocol was predefined and performed by retrospective review of charts and routinely collected data. Results for ICU admissions during September 2002 were compared to those for ICU admissions during September 2001 when there was no protocol for insulin treatment and ad hoc intravenous insulin sliding scales were used.
Basic demographic details are collected for all admissions, and baseline data (anonymous) on age, admission diagnosis, APACHE II score and length of stay were summarized for both time periods. The number of admissions with a recorded blood glucose greater than 7 mmol/l and the time to starting insulin after this first high blood glucose value were compared for the two time periods.
For both time periods, mean blood glucose was calculated for: a. the time on insulin for all ICU admissions started on insulin, b. the whole ICU stay for all ICU admissions started on insulin, assuming the blood glucose remained constant between ICU admission and the first measured value, c. the whole ICU stay for all ICU admissions, making the same assumption. The number of blood glucose values between 2.2 and 3 mmol/l and below 2.2 mmol/l while intravenous insulin was being used were recorded.
The number of admissions receiving intravenous nutrition was recorded for both time periods.
Admissions with a length of stay of less than six hours in ICU were excluded.
A further, post hoc analysis was done to investigate the mean blood glucose for those admissions with recorded blood glucose greater than 7 mmol/l but who had not been started on insulin.
The chairman of the local ethics committee was consulted and concluded that as the study was putting research into practice, no formal approval was required.
Statistical Methods
Mean blood glucose of an admission was calculated for an individual admission by first drawing a graph of blood glucose against time. The area under this glucose/time curve was then calculated and divided by the total time to give the mean blood glucose for that admission. As the time to starting insulin and mean blood glucose are not normally distributed, the median was used for measuring central tendency and the Wilcoxon rank-sum test for comparisons.
RESULTS
Development Phase
The optimized changes in insulin infusion rates in response to blood glucose changes are shown in Figure 1 . Figure 2 shows the guidance notes accompanying the protocol which were developed from the qualitative audit. These describe making up the infusion, the initial starting rate, the frequency of blood glucose testing and other practical issues discussed below.
If enteral nutrition was stopped, glucose control was maintained by halving the insulin infusion rate. The protocol initially specified an automatic increase in the insulin infusion rate when feeding recommenced but this was found to be unnecessary.
The use of dextrose for drug dilution (e.g. for antibiotics or amiodarone) results in a temporary increase in insulin requirement during drug administration, and can be followed by rebound hypoglycaemia. Our unit policy has changed to minimize the use of dextrose. Care should be taken during immunoglobulin infusions as maltose can cause the Advantage meter to over-estimate blood glucose levels.
Concerns about hypokalaemia led to potassium initially being measured two-hourly, though this was later changed to four-hourly with no adverse effects. During the study period, 60 mmol of potassium chloride was given over six hours intravenously to all patients with potassium less than 4 mmol/l and without contraindications.
Audit of the first month of routine use
Charts were available for all ICU admissions during the study periods. Three admissions from 2001 and two from 2002 had no blood glucose readings recorded. Five admissions were excluded: in 2001 two had a length of stay less than six hours and one had diabetic ketoacidosis, in 2002 one was a child and one had DKA. Details of all other admissions are shown in Table 1 . During routine use the protocol was not discontinued except for admissions no longer requiring insulin, those who began to take an oral diet or those ready to be transferred to a ward.
Results are shown in Table 2 . Use of the Bath Insulin Protocol resulted in good blood glucose control whilst admissions were on insulin and there was a highly significant improvement from the previous year when ad hoc sliding scales were used (median 6.2 mmol/l in 2002 compared to 9.2 mmol/l in 2001, P<0.0001). The blood glucose levels for admissions on insulin, for all the time in ICU were also improved (median 6.6 mmol/l in 2002 compared to 8.6 mmol/l in 2001, P=0.0002), as was overall mean blood glucose for all ICU admissions, for all the time in ICU (median 6.5 mmol/l in 2002 compared to 7.2 mmol/l in 2001, P=0.016). The three values of blood glucose below 2.2 mmol/l occurred in three different admissions. Two of them occurred as a rebound following administration of antibiotics diluted in large volumes of dextrose. None were associated with neurological sequelae.
Intravenous nutrition was received by two patients Exclusions This protocol is NOT suitable for children, patients with diabetic ketoacidosis or patients who are eating. Start protocol when blood sugar rises above 7 mmol/l.
Insulin Infusion
Use Insulin Actrapid 50 IU in 50 ml 0.9% NaCl running through a dedicated cannula or central line lumen. Round insulin infusion rates to the nearest 0.5 ml/hr.
Starting rate for insulin infusion
Blood glucose (mmol/l) Rate (ml/h) >12 4 7.1-12 2 3-7 0 <3
give 20 ml 50% glucose, recheck glucose in 30 mins, discuss with doctor.
Blood glucose testing
Initially test blood glucose each hour. Use the same blood glucose testing machine each time.
If blood glucose is stable between 4 and 7 and the insulin dose has only changed by 1 ml/h or less in the last 2 hours, blood glucose can be measured every 2 hours.
Feeding
When enteral feeding is stopped, halve the insulin infusion and measure blood glucose hourly. When enteral feed is restarted, measure the blood glucose hourly and simply follow the protocol (i.e. do not automatically increase insulin infusion when feed goes on).
Stop protocol when patient taking food orally (even if NG supplements being given at night). Consider if insulin necessary by another route.
Other Infusions (especially antibiotics)
Should be made up with water or saline if possible, or if not, with the minimum volume of glucose. Immunoglobulin infusion may cause over reading of blood glucose.
Ward Discharge
Patients should be converted to a standard sliding scale before ward discharge. This should always run with a glucose or TPN infusion. 
DISCUSSION
The principal finding of this study is that during the first month of use of the Bath Insulin Protocol, it provided effective control of median blood glucose below 7 mmol/l. This resulted in overall median blood glucose for these admissions and median blood glucose for all ICU admissions being well controlled. All measures of glucose control were significantly better than in the same time period the previous year when ad hoc sliding scales had been used.
Van den Berghe 1 used a target blood glucose range of 4.4 to 6.1 mmol/l for intensive insulin therapy. We were concerned about the risks of hypoglycaemia if we tried to repeat this, so chose to use the wider target range of 4 to 7 mmol/l. On admission, all patients in the Van den Berghe study were fed continuously with intravenous glucose (200 to 300 g per 24 hours), and the next day total parenteral, combined parenteral and enteral, or total enteral feeding was instituted. Our practice is not to use intravenous glucose feeding, and only two patients during the study period had parenteral nutrition. Enteral nutrition was started as soon as possible after admission to our ICU.
The Accu-Chek Advantage II blood glucose meter oxidizes glucose by means of glucose dehydrogenase, during which hexacyanoferrate III is reduced to hexacyanoferrate II which is then reoxidized, releasing electrons proportional to the glucose concentration of the sample. Laboratory evaluation studies [13] [14] [15] have classified the Advantage system as clinically good by acceptance analysis and clinically acceptable by error grid analysis when using arterial, venous and capillary blood.
Despite having a protocol for glucose control and an active interest from both medical and nursing staff, only 56% of eligible patients with a blood glucose above 7 mmol/l were started on insulin and a median time of nine hours elapsed between an elevated blood glucose being recorded and insulin being started. Audit of those admissions who had at least one elevated blood glucose and who were not started on insulin showed their median mean blood glucose was below 7 mmol/l, suggesting that for these admissions, the periods of elevated blood glucose were either of short duration or that blood glucose was only marginally elevated.
It is unsurprising that insulin was started on a higher percentage of eligible patients with blood glucose greater than 7 mmol/l in 2002 than in 2001 as no protocol existed for glucose control in 2001. The improvement in blood glucose control between the two time periods should also be interpreted cautiously and may not all be attributable to use of the protocol. Differences in patient population may be responsible for the difference seen, and an increased realisation of the importance of tight glucose control may have led to improvement even if ad hoc sliding scales were still used.
The main strength of this study is that it provides detailed documentation of the development of a new insulin protocol, as well as initial data on safety and effectiveness in the critically ill. We are unaware of any publication detailing the development and auditing of an intravenous insulin protocol for use in critically ill patients with a target blood glucose range similar to that used by Van Den Berghe 1 . It is therefore difficult to judge how well the Bath Insulin Protocol performs compared to others. We would caution against implementation of this protocol until effectiveness and safety have been audited in a larger 315 
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Anaesthesia and Intensive Care, Vol. 32, No. 3, June 2004 patient population. We would also caution against implementation of the protocol without reviewing other factors which can lead to fluctuations in blood glucose, e.g. the use of dextrose for drug dilution.
This study raises questions about the most useful measure of blood glucose control. Van den Berghe used the mean morning blood glucose value 1 , though did not define it. We believe that the overall median blood glucose whilst a patient is receiving insulin is likely to provide a better measure of the effectiveness of the protocol while it is used. However, it provides no indication of overall glucose control. A patient could have a long period of elevated blood glucose before starting or after finishing the protocol, so for this reason the overall median value for the whole of these patients' stay was also calculated. Summarizing the median blood glucose for all ICU admissions provides an overall measure of how well intensive insulin therapy is being implemented. Achieving good control with this latter measure requires admissions with high blood glucose to be identified early and started on an effective insulin protocol. We suggest that any further reports of insulin protocol development should include all three measures.
In conclusion, this study provides early data suggesting that the Bath Insulin Protocol results in effective blood glucose control. Further work is necessary to provide safety and effectiveness data for the Bath Insulin Protocol for a larger patient population.
DISCLAIMER
While every effort has been made to ensure its accuracy, users of this protocol are reminded that this is a template. The responsibility for prescribing medication rests with the individual clinician after consideration of the patient's needs.
